NCT00400582View on ClinicalTrials.gov

A Pharmacogenomic Study of Candesartan in Heart Failure

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Heart Failure
Interventions
DRUG

Candesartan up to 32 mg daily

Candesartan 4 to 32 mg daily

Trial Locations (1)

H1T 1C8

Montreal Heart Institute, Montreal

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Montreal Heart Institute

OTHER